Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt to Equity (2016 - 2021)

Lineage Cell Therapeutics (LCTX) has 6 years of Debt to Equity data on record, last reported at $0.0 in Q1 2021.

  • For Q1 2021, Debt to Equity changed N/A year-over-year to $0.0; the TTM value through Mar 2021 reached $0.0, changed N/A, while the annual FY2020 figure was $0.01, N/A changed from the prior year.
  • Debt to Equity reached $0.0 in Q1 2021 per LCTX's latest filing, down from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.01 in Q3 2020 and bottomed at $0.0 in Q4 2017.
  • Average Debt to Equity over 3 years is $0.0, with a median of $0.0 recorded in 2021.
  • The widest YoY moves for Debt to Equity: up 73.27% in 2017, down 88.08% in 2017.
  • A 3-year view of Debt to Equity shows it stood at $0.0 in 2017, then surged by 4917.24% to $0.01 in 2020, then dropped by 18.39% to $0.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.0 in Q1 2021, $0.01 in Q4 2020, and $0.01 in Q3 2020.